1969
DOI: 10.1001/archderm.100.6.655
|View full text |Cite
|
Sign up to set email alerts
|

Parenteral methotrexate in psoriasis. A report on the efficacy and toxicity of long-term intermittent treatment

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

1970
1970
2017
2017

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 19 publications
(3 citation statements)
references
References 21 publications
0
3
0
Order By: Relevance
“…The aetiology is multifactorial with genetic factors as well as extrinsic factors playing important roles. Despite in the past psoriasis was counted among the intrinsic keratinocytes abnormalities [15] and treated with methotrexate [16], in the last 40 years this statement has been revisited. In fact, the evidence of beneficial effects of cyclosporine and denileukin diftitox (toxical agent for T lymphocytes) on psoriasis and psoriatic arthritis has led to the hypothesis of psoriasis as immunological disease [17].…”
Section: Il-17 and Psoriasismentioning
confidence: 99%
“…The aetiology is multifactorial with genetic factors as well as extrinsic factors playing important roles. Despite in the past psoriasis was counted among the intrinsic keratinocytes abnormalities [15] and treated with methotrexate [16], in the last 40 years this statement has been revisited. In fact, the evidence of beneficial effects of cyclosporine and denileukin diftitox (toxical agent for T lymphocytes) on psoriasis and psoriatic arthritis has led to the hypothesis of psoriasis as immunological disease [17].…”
Section: Il-17 and Psoriasismentioning
confidence: 99%
“…Exacerbation of UV‐induced erythema has been reported 56 . Other rare side effects include alopecia and necrosis or ulceration of psoriatic skin lesions 57 . Pulmonary toxicity with fibrosis, which is not dose‐related, is manifested by a nonproductive cough, fever, shortness of breath with chest radiographic changes of interstitial infiltrates.…”
Section: Other Adverse Effectsmentioning
confidence: 99%
“…Usual dosage schedules used in Europe include weekly administration in the range of 10–35 mg orally or intramuscularly. More frequent administration appears to be associated with a higher frequency of hepatic fibrosis 57,59 , 60 …”
Section: Usesmentioning
confidence: 99%